NATCO Pharma

    NATCOPHARM
    Pharma
    ₹820.60
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹16,098 Cr

    P/E
    17.88
    Day range
    ₹818.10 – ₹832.85
    52-week range
    ₹773.60 – ₹1,226.80
    Volume
    11.14 L
    Open
    ₹823.80
    Prev close
    ₹822.90

    Latest results · Q2 FY27(consolidated)Revenue ₹967 Cr-29.0%Profit ₹203 Cr-60.9%Margin 20.9%YoY vs the same quarter last year

    3 red flags to read up on

    • medium

      Promoter pledge went up

      0.94% of promoter shares pledged, up from 0.00% · 23 Oct 2026

    • medium

      Promoters selling in the market

      Promoter group sold a net ₹5.0 Cr on the open market in 90 days · 14 Oct 2026

    • medium

      Promoter holding falling

      46.22%, down 3.26 pts since 2025-12-31 · 23 Oct 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Factor percentiles

    Value85
    Quality54
    Momentum—
    Low volatility—

    Derived metrics

    Earn. yield
    5.6%
    Graham no.
    ₹713.88
    vs Graham
    -13.0%
    ROE ÷ P/B
    11.0%
    Magic Formula
    #147
    Piotroski
    1/6
    FCF yield
    8.6%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    NATCO PharmaNATCOPHARM₹16,098 Cr17.881.5316.9%17.0%27.0%0.11-29.1%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1d ago

    Headlines about NATCO Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    19.6
    Price / Book
    1.52
    ROE (FY26)
    16.9%
    ROCE (latest year)
    17%
    Dividend yield
    0.60%

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.6%
    Profit 3Y CAGR
    +25.6%
    Revenue YoY (Sep 2026)
    -29.1%
    Profit YoY (Sep 2026)
    -60.8%
    Operating margin
    27.0%
    Net margin
    21.0%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%30%60%

    Who owns the company

    % of equity by quarter, latest Oct 2026

    Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '26Oct '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY23FY24FY25FY26FY27₹0₹2.5₹5₹7.5₹10

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales7591,0681,3631,3714751,2211,3291,363647739735967
    YoY Sales growth————-37—-2-1—-39-45-29
    Expenses490571558567436673758784489612549709
    Operating Profit26849780580439548571579159128186258
    OPM %35%47%59%59%8%45%43%42%25%17%25%27%
    Other Income37424864176666210058785952
    Interest565441031310111318
    Depreciation445644464798585246504749
    Profit before tax256478804818164506572614161144186243
    Tax %17%19%17%17%19%20%16%16%13%-62%34%29%
    Net Profit213386668676132406480518151269206203
    EPS in Rs₹11.78₹21.39₹37.02₹37.50₹7.36₹22.51₹26.62₹28.70₹8.39₹14.83₹11.43₹11.22

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days79

    +6 days since Mar 2021

    Inventory Days480

    -90 days since Mar 2021

    Days Payable216

    +112 days since Mar 2021

    Cash Conversion Cycle343

    -196 days since Mar 2021

    Working Capital Days111

    -135 days since Mar 2021

    Strengths, risks & growth

    NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business. [2]

    Strengths

    • Company has delivered good profit growth of 28.1% CAGR over last 5 years

    Risks

    • Promoter holding has decreased over last quarter: -3.19%
    • Tax rate seems low
    • Earnings include an other income of Rs.247 Cr.

    Compounded Sales Growth

    10 Years
    +15%
    5 Years
    +15%
    3 Years
    +15%
    TTM
    -30%

    Compounded Profit Growth

    10 Years
    +25%
    5 Years
    +28%
    3 Years
    +27%
    TTM
    -46%

    Stock Price CAGR

    10 Years
    +3%
    5 Years
    +1%
    3 Years
    +2%
    1 Year
    +2%

    Return on Equity

    10 Years
    +19%
    5 Years
    +19%
    3 Years
    +23%
    Last Year
    +17%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderMar 2026Jun 2026Sept 2026Oct 2026Change
    Promoter49.41%49.41%49.39%46.22%-3.17 pp
    FII17.37%16.99%15.99%15.37%-0.62 pp
    DII5.46%5.63%6.16%10.82%+4.66 pp
    Public27.74%27.97%28.46%27.59%-0.87 pp

    Filed with NSE for Oct 2026: promoters 46.22%, public 53.78%

    Analysts & fund holdings

    64%
    64% recommend buy
    11 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E17.9 vs 45.2
    Sector P/B6.05
    Beta0.83

    Who holds the shares, quarter by quarter

    Mutual funds 7.01% (+4.76 pp)
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    Oct 26
    • Promoters46.2%
    • Foreign institutions15.4%
    • Mutual funds7.0%
    • Insurance3.6%
    • Other domestic institutions0.2%
    • Retail19.6%
    • Others8.0%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Tata Small Cap Fund1.25%1.72%+1.32 pp
    ICICI Pru Contra Fund0.64%6.59%+6.59 pp
    Nippon India Growth Mid Cap Fund0.52%0.17%+0.17 pp
    Nippon India Pharma Fund0.50%0.90%+0.90 pp
    ICICI Pru Manufacturing Fund0.46%1.14%+1.14 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    1 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹1,377 Cr
    FCF yield
    8.6%
    Cash conversion
    1.25
    Accruals ratio
    -0.032
    Net debt
    ₹515 Cr
    Net debt / equity
    0.06
    EV / sales
    5.38
    Capex intensity
    9.6%
    Revenue CAGR
    -39.5%
    Profit CAGR
    -33.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹146 Cr
    26 buys · ₹168 Cr
    21 sells · ₹21.9 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    VENKAIAH CHOWDARY NANNAPANENI
    Promoter and Director · Allotment
    Buy5,86,666₹44.0 Cr29 Oct 2026
    NEELIMA SITA NANNAPANENI
    Promoter · Allotment
    Buy2,55,387₹19.2 Cr29 Oct 2026
    RAJEEV NANNAPANENI
    Promoter and Director · Allotment
    Buy58,666₹4.4 Cr29 Oct 2026
    TIME CAP PHAMA LABS PVT LTD
    Promoter Group · Allotment
    Buy9,33,333₹70.0 Cr29 Oct 2026
    NATSOFT INFORMATION SYSTEMS PVT LTD
    Promoter Group · Allotment
    Buy2,40,000₹18.0 Cr29 Oct 2026
    NATCO AQUA LIMITED
    Promoter Group · Allotment
    Buy1,523₹11.4 L29 Oct 2026
    VISTRA ITCL LIMITED A/C NEELIMA TRUST
    Promoter · Allotment
    Buy69,785₹5.2 Cr29 Oct 2026
    VISTRA ITCL LIMITED A/C VCN FAMILY TRUST
    Promoter · Allotment
    Buy161₹1.2 L29 Oct 2026
    SAU FAMILY TRUST
    Promoter · Allotment
    Buy161₹1.2 L29 Oct 2026
    V S SWATHI KANTAMANI
    Promoter Group · Allotment
    Buy61,333₹4.6 Cr29 Oct 2026
    KANTAMANI RATNA KUMAR
    Promoter Group · Allotment
    Buy4,761₹35.7 L29 Oct 2026
    LINGARAO DONTHINENI
    Director · Allotment
    Buy5,157₹38.7 L29 Oct 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      19 Nov 2026
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 2:21 @ Premium Rs 748/-

      1 Oct 2026
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      20 Aug 2026
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      18 Feb 2026
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      20 Nov 2025
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      19 Aug 2025
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      18 Feb 2025
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      27 Nov 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      25 Sept 2024
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      23 Aug 2024
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      26 Feb 2024
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      24 Nov 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      25 Sept 2023
      ex-date
    • dividend
      ₹7.00

      Interim Dividend - Rs 7 Per Share

      22 Aug 2023
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      21 Feb 2023
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 0.75 Per Share

      21 Nov 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Sept 2022
      ex-date
    • dividend
      ₹3.50

      Interim Dividend - Rs 3.50 Per Share

      19 Aug 2022
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      24 Feb 2022
      ex-date
    • dividend
      ₹0.50

      Interim Dividend - Rs 0.50 Per Share

      23 Nov 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Sept 2021
      ex-date

    Company announcements

    Insider Trading / SAST
    Closure of Trading Window

    Update on Trading Window Closure period

    Company Update
    Intimation Of Closure Of The Issue Period Of The Rights Issue Of NATCO Pharma Limited (The 'Company')

    Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Reg.74(5) of SEBI(DP) Regulations, 2018

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2026 for V C Nannapaneni

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    News Paper Publications

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/2026

    Insider Trading / SAST
    Closure of Trading Window
    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the 43rd Annual General Meting

    Others
    Board Meeting Outcome for Outcome Of Fund Raising Committee Meeting Approving The Letter Of Offer For Rights Issue

    Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication of Record date for Rights Issue

    Corp. Action
    Intimation Of Record Date For Rights Issue

    Intimation of Record Date for Rights Issue

    Company Update
    Announcement under Regulation 30 (LODR)-Issue of Securities

    Out come of Board Meeting

    Board Meeting
    Board Meeting Outcome for Out Come Of Board Meeting

    Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : ....

    Filed with BSE (scrip 524816); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Buyback

      NATCO Pharma Limited

      10 Mar 2023
      Read on SEBI
    • Buyback - Corrigendum to Public Announcement

      Natco Pharma Limited – Corrigendum to Public Announcement

      19 Mar 2019
      Read on SEBI
    • Buyback - Public Announcement

      Natco Pharma Limited – Public Announcement

      14 Nov 2018
      Read on SEBI
    • Open offer

      Natco Pharma Limited

      5 Feb 2007
      Read on SEBI
    • Buyback - Public Announcement

      Natco Pharma Limited - Public Announcement

      6 Sept 2006
      Read on SEBI

    Regulatory orders

    • Order

      Order in the matter of Natco Pharma Limited

      5 Jan 2007
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 13 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    NATCO Pharma: common questions

    Answered from the figures on this page.

    NATCO Pharma last traded at ₹820.60 (NSE, as of 18 Nov 2026). The last session moved it down 0.28%.

    NATCO Pharma is valued at about ₹16,098 crore (NSE, as of 18 Nov 2026).

    NATCO Pharma trades at a price-to-earnings ratio of 17.88 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    NATCO Pharma has traded between ₹773.60 and ₹1,226.80 over the past 52 weeks, to 18 Nov 2026. It is currently 10% of the way up that range.

    NATCO Pharma (NATCOPHARM) is classified under Pharma on this site's screener.